RT Journal Article
SR Electronic
T1 Ad26.COV2.S or BNT162b2 Boosting of BNT162b2 Vaccinated Individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.02.21267198
DO 10.1101/2021.12.02.21267198
A1 Tan, C. Sabrina
A1 Collier, Ai-ris Y.
A1 Liu, Jinyan
A1 Yu, Jingyou
A1 Wan, Huahua
A1 McMahan, Katherine
A1 He, Xuan
A1 Jacob-Dolan, Catherine
A1 Chandrashekar, Abishek
A1 Sellers, Daniel
A1 Stephenson, Kathryn E.
A1 Vidal, Samuel J.
A1 Jaegle, Kate
A1 Curran, Jessica L.
A1 Rowe, Marjorie
A1 Hemond, Rachel
A1 Rivera, Lorraine Bermudez
A1 Anioke, Tochi
A1 Barrett, Julia
A1 Chung, Benjamin
A1 Gardner, Sarah
A1 Gebre, Makda S.
A1 Lifton, Michelle
A1 Powers, Olivia
A1 VanWyk, Haley
A1 Wu, Cindy
A1 Barouch, Dan H.
YR 2021
UL http://medrxiv.org/content/early/2021/12/05/2021.12.02.21267198.abstract
AB Previous studies have reported that a third dose of the BNT162b2 (Pfizer) COVID-19 vaccine increased antibody titers and protective efficacy. Here we compare humoral and cellular immune responses in 65 individuals who were vaccinated with the BNT162b2 vaccine and were boosted after at least 6 months with either Ad26.COV2.S (Johnson & Johnson; N=41) or BNT162b2 (Pfizer; N=24).Competing Interest StatementDHB is a co-inventor on provisional vaccine patents (63/121,482; 63/133,969; 63/135,182). The authors report no other conflict of interest.Clinical TrialNCT04999111Funding StatementThe authors acknowledge Janssen Vaccines & Prevention, NIH grant CA260476, the Massachusetts Consortium for Pathogen Readiness, the Ragon Institute, and the Musk Foundation (D.H.B.). The authors also acknowledge the Reproductive Scientist Development Program from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and Burroughs Wellcome Fund HD000849 (A.Y.C.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The BIDMC institutional review board approved this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript